Pacific biosciences of california, inc. (PACB)
CashFlow / Yearly
Dec'19Dec'18Dec'17Dec'16Dec'15Dec'14Dec'13Dec'12Dec'11Dec'10Dec'09
Cash flows from operating activities
Net income (loss)

-84,134

-102,562

-92,189

-74,375

-31,696

-66,160

-79,293

-94,465

-109,388

-140,166

-87,703

Adjustments to reconcile net loss to net cash used in operating activities
Gain from Continuation Advances

18,000

-

-

-

-

-

-

-

-

-

-

Depreciation

7,265

7,215

8,442

3,875

3,677

4,221

5,648

6,649

5,803

5,160

4,104

Amortization of right-of-use assets

2,683

-

-

-

-

-

-

-

-

-

-

Amortization of debt discount and financing costs

1,212

1,024

1,203

1,158

957

793

595

-

-

-

-

Non-cash portion of gain on lease amendments

-

-

-

-

-3,043

-

-

-

-

-

-

Gain on derivative

16

167

-653

244

344

-

-

-

-

-

-

Stock-based compensation

16,401

23,153

20,352

19,562

13,840

9,943

9,905

9,705

12,384

9,690

3,630

Amortization (accretion) from investment premium (discount)

913

758

32

-97

-

-

-

-

-

-

-

Loss on disposition of equipment

-194

-

-11

-

-

-

-

-

-

-

-

Loss on return of building under capital lease

-

-

-68

-

-

-

-

-

-

-

-

Other items

-

-

-

-

-114

-507

352

-1,295

-226

-459

-194

Changes in assets and liabilities
Accounts receivable

6,671

-4,838

2,012

6,176

1,738

660

-76

-1,735

4,216

341

-

Inventory

-3,915

-3,623

8,442

6,151

2,466

1,285

60

-4,761

11,409

6,864

-

Prepaid expenses and other assets

523

290

-7,803

202

17,889

224

-840

-50

-1,874

1,336

30

Accounts payable

1,713

-2,239

764

3,402

-716

3,891

-1,271

-1,754

-4,773

3,637

3,891

Accrued expenses

419

205

-3,986

1,053

5,732

3,536

1,327

-1,333

-

4,245

1,168

Deferred revenue

-2,134

-33

1,033

469

708

2,686

386

-1,674

2,631

3,221

-

Operating lease liabilities

3,428

-

-

-

-

-

-

-

-

-

-

Deferred contractual revenue

-

-

-

-12,134

-14,386

-6,784

33,304

-

-

-

-

Other liabilities

-563

-505

880

1,737

-639

-1,932

-938

-1,791

3,044

-

-

Deferred rent and other long-term liabilities

-

-

-

-

-

-

-

-

850

299

-92

Net cash provided by (used in) operating activities

-78,312

-66,430

-67,518

-67,929

-47,889

-51,468

-29,833

-76,822

-102,974

-121,996

-74,838

Cash flows from investing activities
Purchase of property and equipment

2,836

1,854

10,433

8,207

3,009

1,609

909

1,703

9,284

5,259

5,177

Proceeds from disposal of property and equipment

-

-

41

10

36

-

-

-

-

-

-

Decrease in Long-term restricted cash

-

-

-

-

4,500

-

-

-

-

-

-

Purchase of investments

57,727

122,183

86,339

95,848

84,579

126,413

201,547

87,889

264,071

180,964

25,429

Sales of investments

1,500

2,442

7,111

23,285

8,317

-

100

7,896

36,520

-

-

Maturities of investments

121,110

83,180

88,071

65,896

92,341

147,586

169,239

143,488

243,281

47,973

49,200

Net cash provided by (used in) investing activities

62,047

-38,415

-1,549

-14,864

8,606

19,564

-33,117

61,792

6,446

-138,250

18,594

Cash flows from financing activities
Proceeds from Continuation Advances

18,000

-

-

-

-

-

-

-

-

-

-

Proceeds from exercise of Junior Preferred Stock options

-

-

-

-

-

-

-

-

-

-

1

Repurchases of Common Stock

-

-

-

-

-

-

-

-

-

-

8

Notes payable principal payoff

-

-

4,500

-

-

-

-

-

-

-

1,300

Proceeds from issuance of Convertible Preferred Stock, net

-

-

-

-

-

-

-

-

-

106,145

68,010

Proceeds from issuance of common stock from equity plans

8,548

9,652

8,914

7,729

7,363

3,968

3,079

2,705

7,743

212,519

311

Proceeds from issuance of debt agreement, net of issuance costs

-

-

-

-

-

-

19,766

-

-

-

-

Net cash provided by financing activities

26,548

107,182

68,809

65,929

36,463

41,991

42,772

2,705

7,743

318,664

67,014

Net increase in cash and cash equivalents and restricted cash

10,283

2,337

-258

-16,864

-2,820

10,087

-20,178

-12,325

-88,785

58,418

10,770

Supplemental disclosure of cash flow information
Interest paid

1,400

1,400

1,687

1,799

1,794

1,794

1,165

-

-

-

30

Supplemental disclosure of non-cash investing and financing activities
Inventory transferred to property and equipment

2,062

1,871

1,267

1,282

2,846

-

-558

1,164

2,756

-

-

Property and equipment transfered to inventory

1,536

343

261

-

-

-

-

-

-

-

-

Assets acquired under facility lease

-

-

-

-

-

-

-

-

-

2,971

-

Property and equipment paid for by landlord

-

-

12,600

-

-

-

-

-

-

1,910

-

Changes in deposits for property and equipment paid in prior period

-

-

9,694

-

-

-

-

-

-

-

-

Property and equipment returned to landlord

-

-

1,854

-

-

-

-

-

-

-

-

Conversion of convertible preferred stock to common stock upon IPO

-

-

-

-

-

-

-

-

-

374,965

-

Reclassification of preferred warrants to common stock warrants

-

-

-

-

-

-

-

-

-

326

-

Issuance of common stock related to convertible preferred stock offering

-

-

-

-

-

-

-

-

-

281

-

Vesting of stock options related to early exercises

-

-

-

-

-

-

-

-

-

428

-

At the Market Offering [Member]
Proceeds from issuance of common stock from offering, net of issuance costs

-

-

11,865

58,200

-

38,023

19,927

-

-

-

-

Underwritten Public Equity Offering [Member]
Proceeds from issuance of common stock from offering, net of issuance costs

-

97,530

52,530

-

-

-

-

-

-

-

-